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Abstract
We examined the relationship of clinical differences among sickle cell disease (SCD) patients in
order to understand the major contributors to early mortality in a contemporary cohort.
Survival data were obtained for 542 adult subjects who were enrolled since 2002 at three
university hospitals in the southeast United States. Subjects were followed for a median of 9.3
years. At enrollment, clinical parameters were collected, including hemoglobin (Hb) genotype,
baseline laboratory values, comorbidities, and medication usage. Levels of soluble adhesion
molecules were measured for a subset of 87 subjects. The relationship of clinical characteristics to
survival was determined using regression analysis.
Median age at enrollment was 32 years. Median survival was 61 years for all subjects. Median
survival for Hb SS and Sβ0 was 58 years and for Hb SC and Sβ+ was 66 years. Elevated white
blood count, lower estimated glomerular filtration rate, proteinuria, frequency of pain crises,
pulmonary hypertension, cerebrovascular events, seizures, stroke, sVCAM-1 and short-acting
narcotics use were significantly associated with decreased survival. 42% of subjects were on
hydroxyurea therapy, which was not associated with survival.
SCD continues to reduce life expectancy for affected individuals, particularly those with Hb Sβ0
and SS. Not only were comorbidities individually associated with decreased survival, but an
additive effect was observed, so that those with a greater number of negative endpoints had worse
survival (p<0.0001). The association of higher sVCAM-1 levels with decreased survival suggests
that targeted therapies to reduce endothelial damage and inflammation may also be beneficial.
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BACKGROUND
While it is clear that survival of sickle cell disease (SCD) patients has improved over the last
40 years, the factors that portend positive and negative prognoses need be readdressed given
the development of new treatment modalities, such as stem cell transplantation, that hold
promise for cure but also carry considerable risk. SCD patients are now living long enough
that many patients, families, and physicians might not wish to incur further risk in order to
obtain a chance at cure. Thus, in order to give patients and physicians the opportunity to
make informed decisions, more detailed data are needed to identify truly favorable and
unfavorable phenotypic traits and thus help better identify individualized treatment options
for patients with this disease.
Sickle cell disease was long a disease of children and young adults due to its devastating
natural progression. In the 1970s, studies estimated the median survival of homozygotes in
the United States to be only 14.3 years.[1]Since that time, a number of interventions have
been implemented to improve quality and duration of life.[2–5] With modern advances, the
survival of patients with SCD was estimated in the 1990’s to be 42 years for males and 48
years for females.[6]
Clearly, SCD is manifested by diverse presentations, and its prognosis varies across the
patient population. Most notably, hemoglobin (Hb)genotype influences severity of disease.
Hemoglobin SS has a significantly lower survival than Hb SC disease and Sβ+ thalassemia.
[2, 6] Within these groups, therefore, research has focused on identifying phenotypes that
predict an unfavorable prognosis. Prior studies have shown renal failure, seizures, acute
chest syndrome (ACS), low fetal Hb level, and baseline white blood cell (WBC) count
greater than 15,000 cells per cubic millimeter to be associated with decreased survival.
[6]Among SCD patients on hydroxyurea therapy, it has been shown that higher total Hb,
fetal Hb, reticulocyte counts, and fewer instances of acute chest syndrome were all
associated with improved survival.[7]
Molecular phenotypes and biomarkers have become a new topic of investigation.[8] In
particular, endothelial proteins that contribute to adhesion—such as VCAM-1, ICAM-1,
alphaVbeta3 integrin, P-selectin, and E-selectin—have been described as contributors to the
pathophysiology of vaso-occlusive crises.[9–18]Some of these proteins have been shown to
circulate in free, soluble form at elevated levels in SCD patients. In addition, in SCD
patients with crises, increased expression of these molecules on endothelial cells has been
demonstrated.[19, 20]Some studies have even suggested that the ability of hydroxyurea to
decrease vaso-occlusive crises, long thought to be mediated by upregulation of fetal Hb,
may actually also be related to downregulation of adhesion proteins and their ligands.[21–
23]These correlations suggest that adhesion proteins are potentially useful targets for
prognostication as well as novel treatments for SCD.
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The goal of this study was to identify associations between the presence of certain clinical
phenotypes at enrollment, such as comorbid conditions and laboratory data, and decreased
survival among SCD patients in a contemporary cohort.
METHODS
Subjects
Institutional Review Board approval was obtained and subjects were enrolled at their
respective institutions. The present analysis included 542 adult subjects (≥ 18 years at the
time of enrollment) diagnosed with SCD(Hb SS, SC, Sβ0, or Sβ+) by hemoglobin
electrophoresis, globin synthesis gene studies, or genetic analysis who were regularly
followed in clinic at Duke University Medical Center, the University of North Carolina
Health Care System, and Grady Health System. Subjects who had received blood
transfusion within 90 days prior to enrollment were excluded.
Study Design
At the time of enrollment, we evaluated subjects for characteristics suspected to influence
mortality of patients with SCD using a standardized validated patient history questionnaire,
[24] laboratory data, and medical chart review. Included subjects were followed for a
median of 9.3 years(minimum 2.7, maximum 10.5 years). The primary endpoint was death
during the follow-up period. Using a cross-sectional design, associations between baseline
characteristics present at enrollment and decreased survival were determined. Baseline
characteristics included comorbid conditions, baseline laboratory values, pain, and
medication use, as shown in Tables I, II, and III.
For comorbidities at enrollment, any history of the event, whether ongoing or resolved, was
considered as positive. Pulmonary hypertension (pHTN) was defined as a tricuspid
regurgitant jet (TR jet) ≥2.5 m/s. When available, laboratory values included the average of
three recent steady state values to account for outliers. Laboratory data obtained during
acute illness were excluded. Using these data, we calculated and included the hemolytic
index (defined as the first principal component of LDH, AST, bilirubin and reticulocyte
count).[25]In a subset of 87 subjects from Duke University and the University of North
Carolina, we also obtained levels of plasma markers, including soluble adhesion molecules.
Using the patient history questionnaire, pain was evaluated based on the number of
hospitalizations in the past 12 months and use of narcotic analgesics at home. Medication
use was also evaluated with the questionnaire, and our final analysis examined use of
hydroxyurea, migraine medications, bronchodilators, iron chelators, antihypertensives, and
antidepressants.
Using a previously described model,[26] an end organ severity score was generated using
the following parameters: pulmonary (pHTN or O2 saturation < 92%), renal (proteinuria or
creatinine > 1), cerebrovascular (stroke, TIA or seizures), AVN of hip or shoulder, and leg
ulcers. One point was recorded for organ damage in each category. Points were then
summed to create the severity score ranging from 0–5.
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Contingency tables for categorical variables and means for continuous variables were
generated using PROC FREQ and PROC MEANS in SAS v9.2 (SAS Systems, Cary, NC),
respectively. Kaplan-Meier survival curves were created and hazard ratios for mortality
during the study period were calculated to determine baseline characteristics associated with
decreased survival. Kaplan-Meier survival analyses were performed using PROC
LIFETEST; survival curves were created using Prism (GraphPad, Inc.). Regression analysis
based on the Cox proportional hazards model was employed to determine the effect of
clinical phenotypes on survival time using PROC PHREG. All models were adjusted for
gender and age at enrollment. Several diagnostic metrics were employed to confirm that the
assumption of proportional hazards for each model was met, including examination of log-
negative-log survival curves and plots of Schoenfeld residuals (http://support.sas.com/
resources/papers/proceedings13/428-2013.pdf) as well as testing the interaction between




Our study included 542 subjects. The median age at enrollment was 32 years (range 18 to 84
years). Of these, 427 (78.8%) had Hb SS, 70 (12.9%) had Hb SC, 23 (4.2%) had Sβ+, and 22
(4.1%) had Sβ0. Median follow-up time was 9.3 years (range 2.7–10.5 years). At the
conclusion of the study, 128 participants (23.6%) had died. The median age at death was 47
years for females, 44 years for males, and 45 years overall (range 20 to 86 years), as shown
in supplemental Table I. Median survival was 61 years of age for all subjects, with no
difference between males and females.
Table I and supplemental Table II show baseline clinical characteristics of our cohort.
Among our population, 79.4% had graduated high school. Tobacco use was reported by
34.2%. Approximately 42% of all subjects and 45% of HbSS and Sβ0 subjects were on
hydroxyurea at the onset of the study. Eighteen percent of HbSC and 31% of Hb Sβ+
thalassemia subjects were also taking hydroxyurea.
Survival Data
Hemoglobin Genotype—Among sickle cell genotypes, survival curves demonstrated
that HbSS and Sβ0 portended the worst prognoses, followed by Hb SC and Sβ+ (Figure 1A).
Overall median survival for HbSS and Sβ0 was 58 years and for Hb SC and Sβ+ was 66
years, a difference that was statistically significant (p=0.0031). In subjects with Hb SS, the
median age at death was 44.5 years and 25.3% of the subjects had died by the conclusion of
the study, while Hb Sβ0 subjects had a median age at death of 43 years and 40.9% mortality.
However, these differences were not statistically significant (p=0.2188).
Table II shows hazard ratios for dichotomous variables(reported as “present” or “not
present”) and Table III shows hazard ratios for continuous variables.
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Hematologic—As expected, low hemoglobin was associated with poorer survival: for
every g/dL decrease in Hb, the HR increased by 1.2077 (p=0.0043). However, this
association disappeared when correcting for GFR. In addition, with every 103/μ Lincrease in
WBC, the calculated hazard ratio increased by 1.059 (p=0.0419). Hemolytic index was not a
statistically significant factor in survival among HbSS and HbSβ0 subjects (Table III).
Cardiopulmonary—Cardiopulmonary disease is known to be the primary etiology of
death in adult SCD subjects.[27] In our sample, pHTN was present in 32% of SCD subjects.
In our survival analysis, this proved to be a poor prognostic factor (HR=2.3386, p=0.0036).
Similarly, elevated NT-proBNP was a marker of early death (HR=1.617, p=0.0004). While a
diagnosis of hypertension did not correlate with early mortality, SCD subjects who were on
chronic antihypertensive therapy did suffer earlier death than their counterparts.
Neurologic—A history of neurologic disease was present in 32% of subjects and
correlated with early mortality. A history of any cerebrovascular event (CVE), defined as at
least one stroke, seizure, or transient ischemic attack (TIA), was associated with decreased
survival (HR=1.9464, p=0.0005). When analyzed individually, stroke (HR=1.6373,
p=0.0335) and seizure (HR=2.5369, p<0.0001) were still associated with poor prognosis.
Renal—Presence of ≥1+ proteinuria by dipstick, observed in 26% of our sample, was an
indicator of decreased longevity (HR=1.8618, p=0.0014). An association between renal
function and decreased survival was corroborated with estimated GFR,[28] which
demonstrated that the risk of death increased with worsening GFR (HR=1.068 per ml/min
decrease in GFR, p<0.0001).
Hepatobiliary—As shown in Table I, gall bladder disease and cholecystectomy were
among the most frequent comorbid conditions found in our SCD subjects. However, none of
the hepatobiliary disease measures evaluated in our study were associated with survival.
Musculoskeletal/Cutaneous—Leg ulcers were a predictor of early mortality
(HR=1.6631, p=0.0118). A vascular necrosis, while common with a prevalence of 32%, had
no impact on prognosis.
Pain—As shown in Table II, having at least one crisis in the last year was associated with
decreased survival (HR=1.744, p=0.0054, CI=1.18 to 2.58). In our cohort, 56% had suffered
at least one pain crisis in the prior year, and 15% of those were hospitalized greater than four
times. Survival was significantly lower in those who had experienced greater than four
crises compared to those with less than four (Figure 1B, HR=2.1849, p=0.0006). These
results were consistent when restricting the analysis to only subjects with Hb SS or Sβ0.
Similarly, some patterns of narcotic use were related to decreased survival as shown in
Table II.
Biomarkers—Of the evaluated adhesion molecules and inflammatory markers shown in
Table III, only sVCAM-1 levels were associated with decreased survival (HR=2.032,
p=0.0003). This association was also observed when including only subjects with SS or Sβ0
(HR=1.949, p=0.0009).
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Hydroxyurea—Hydroxyurea has previously been shown to decrease mortality in SCD
subjects.[29]Survival of Hb SS or Sβ0 subjects using hydroxyurea therapy was compared to
those subjects not using hydroxyurea, and no difference in survival was observed
(p=0.3228). This analysis was extended to compare hydroxyurea among subjects with the
previously mentioned comorbidities, and no significant improvement in survival was
observed among subjects with specific comorbidities.
Organ System Severity Score—For 493 subjects with SCD, a severity score of 0–5 was
calculated to assess damage to multiple end organs, as defined in the methods section. One
hundred forty-four subjects had a severity score of “0,” 175 scored “1,” 104 scored “2,” 56
scored “3” and 14 subjects scored “4.” No subjects had a severity score of “5.” Subjects with
a score of 0–1 had a favorable prognosis compared to those with scores of >1 (Figure 1C,
HR=1.502, p=0.0263).
DISCUSSION
Previous studies have reported an expected survival of 42 to 48 years in Hb SS subjects and
60 to 68 years in Hb SC subjects.[6] Based on our hazard estimates, median survival in our
population is now 58 years for Hb SS and Sβ0 and 66 years for Hb SC and Sβ+. These data
suggest that medical progress over the last 10–20 years has led to improvement in the
overall survival for patients with Hb SS and Sβ0.
However, these data must be considered with caution. Our study only enrolled adult sickle
cell patients. This exclusion of pediatric sickle cell patients, a small number of whom die in
childhood, may have caused some inflation in our survival estimates. However, recent data
have shown that SCD-related survival to adulthood is nearly 94%[5], suggesting that
exclusion of the pediatric population should not have drastically improved our survival
estimates. Second, 6.18% of our original study population was lost to follow up when we
performed our “look back” for survival. However, it is the impression of the centers
involved that most subjects lost to follow up had simply moved away, although this cannot
be rigorously confirmed. Additionally, the patient population studied was limited to a cohort
of patients from the southeastern United States. Thus, regional variations in comorbid
conditions, such as rates of obesity or tobacco use, might limit the generalizability of our
findings to the entire country. Finally, our subject population, consisting of patients from
three referral centers, may be skewed toward a higher severity of disease than exists in the
community.
In our evaluation of hematologic parameters, Hb level predicted survival, with the risk of
early death inversely correlated to the baseline Hb level. The degree of WBC elevation was
similarly related to survival, with a higher level predicting a shorter survival. However,
when hazard ratios for Hb were corrected for GFR, the detected relationship was no longer
statistically significant. This may suggest that hemoglobin is a biologic marker for the effect
of kidney disease on survival and not independently associated with survival. In contrast to
prior studies,[2, 6] Hb F level did not correlate with mortality in our study, even after
controlling for hydroxyurea use.
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With improvements in antibiosis and vaccination, the primary cause of death among SCD
patients has shifted from infection to cardiopulmonary disease.[27] Our study was not
intended to identify cause of death, but cardiopulmonary disease was clearly a risk factor for
early death. Specifically, elevated tricuspid regurgitant jet velocity (≥2.5 m/s)and pro-BNP
levels were strongly associated with poor survival. Although our study used
echocardiography rather than right heart catheterization to identify subjects with possible or
presumed pulmonary hypertension, thus likely identifying some patients without true
pulmonary arterial hypertension,[30, 31]the use of tricuspid regurgitant jet velocity is a less
invasive surrogate for evaluation with approximately a 25% positive predictive value in
SCD patients.[31]Moreover, our results are consistent with prior studies showing an
association between presumptive pulmonary hypertension, defined similarly by tricuspid
regurgitant jet velocity ≥2.5 m/sec, and early mortality, and are furthermore corroborated by
the significance of an elevated pro-BNP in our analysis.[32]
Treatment with antihypertensive medications was a poor prognostic factor. This is not
surprising, because patients who require antihypertensive medications likely had more
severe hypertension and potentially other secondary comorbidities. However, to further
evaluate this finding, we compared subjects in the highest quartile for both systolic and
diastolic blood pressure to the rest of our sample and found no difference in survival.
Finally, the relationship of antihypertensive medication use to survival was no longer
significant when analyzed with GFR as a covariate. Hence, as some
antihypertensives(specifically ACE inhibitors) are used for renal protection in the setting of
proteinuria, the prognostic significance of these medications may reflect underlying kidney
disease. Nevertheless, our findings do support the need for future studies addressing
therapeutic goals for blood pressure levels and preferred approaches to antihypertensive
therapy and proteinuria in SCD patients.
Pulmonary comorbidities were not related to survival in our sample. The most notable of
these was history of acute chest syndrome, which has been a well-documented prognostic
factor in prior studies.[6, 32]In our methodology, history of ACS was determined by patient
report of ACS or pneumonia, thus leading to some inherent inaccuracy in the reported
prevalence of ACS. Patients who died from ACS prior to enrollment could not be included
in the analysis. Hence, our results cannot be used to show that ACS does not influence
survival. Instead, our findings suggest that there is no change in the long-term survival of
SCD patients who survive an episode of ACS. In addition, asthma, as identified by use of
bronchodilators, also did not affect survival.
During episodes of inflammation and endothelial injury, such as vaso-occlusive crises,
endothelial adhesion molecules are released into the plasma.[20] Hence, we anticipated that
elevations in soluble adhesion molecules would also be related to severity of SCD and
would prove useful in predicting early mortality. Indeed, in this respect, we have confirmed
the findings of Kato, et al.[33] that elevated sVCAM-1 is clearly related to poor prognosis.
This raises the possibility that underlying vascular damage and inflammation is a primary
facilitator of early death in SCD patients, and that future treatments targeting these
inflammatory processes may prove to be life prolonging.
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Our results also underscore the significance of pain in the natural history of SCD. We have
shown associations between survival and pain frequency, hospitalizations due to pain, and
narcotic use, consistent with prior studies.[6]However, the effects of pain on survival may
not be reversible by improvements in pain management alone. Greater frequency and
severity of pain may reflect more severe underlying disease. Further, the relationship
between narcotic use and decreased survival may reflect direct adverse effects of the
medications, such that more aggressive analgesia could worsen survival. Still, adequate
management of SCD pain could yield improvements to patient quality of life,[34]and
prevention of acute pain episodes might also be an effective strategy for decreasing
healthcare costs.[35]
Assessment using our previously developed organ severity score,[26] based on number of
affected organ systems, also showed that, with each additional organ system affected,
survival decreased. The largest incremental risk increase occurred as patients moved from
two involved organ systems to three. Escalation of the severity score from three organ
systems to four did not affect prognosis. However, due to the small number of patients with
a severity score of four, we likely lacked adequate statistical power to detect significant
differences in that analysis.
As we used a cross-sectional design, there are many limitations to our study. Our analysis
could only assess associations between survival and characteristics present at baseline
without proving causality. Additionally, we cannot determine whether subjects developed
new comorbid conditions during the follow-up period nor whether these influenced
prognosis. Our design also cannot be used to determine risk of death from acute
complications of SCD such as ACS, strokes, or seizures. Instead, we hope our results will
help predict the expected survival of SCD patients who have survived such complications
previously. Finally, use of hydroxyurea was neither randomized nor monitored, so findings
regarding the effects of this medication may not reflect ideal use nor comparable
populations.
In conclusion, our survival data highlight improvements in overall survival in SCD patients
over the last decade. Despite this progress, SCD patients continue to experience decreased
quality of life and, ultimately, a shortened life span compared to the general population.
Thus, there is a dire need for new therapeutic options. While we have identified several
predictors of decreased survival, the question remains whether treatments targeted at these
factors would improve mortality. As emerging but riskier therapies such as bone marrow
transplant and gene therapy begin to offer hope for a potential cure,[36] our results may be
useful to help identify high risk patients most in need of these therapies. Furthermore, while
we have identified phenotypes associated with prognosis, it nevertheless remains unclear
why the overall course of SCD is so varied across the patient population. Future studies
identifying genetic variations associated with more severe phenotypes and overall survival
could provide a dramatic improvement in our understanding of SCD, as well as unveil novel
therapeutic targets.
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FIGURE 1A: Survival curves by genotype.
Hb SS and Sβ0 thalassemia subjects (solid line) had a median survival of 58 years. Hb SC
and Sβ+ thalassemia subjects (dotted line) had a median survival 66 years. The difference
between curves is significant (p=0.0031).
FIGURE 1B: Survival curves by frequency of vaso-occlusive pain crises defined as a crisis
requiring inpatient admission. For subjects with 0–4 pain crises/year (dotted line), median
survival was 61 years. For subjects with >4 crises/year, median survival was 53 years.
Hazard ratio was 3.6982 (p<0.0001).
FIGURE 1C: Survival curves by organ severity score.
Degree to which subjects had organ-specific sequelae of SCD was rated on a scale of 0–5, as
described; no subject had a score of >4. Median survival for subjects with a score of 0–1
(dotted line) was 64 years and for subjects with a score >1 was 56 years. Hazard ratio
between the two curves was 1.502 (p=0.0263).
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TABLE I
Prevalence of baseline clinical characteristics at the time of enrollment.
CHARACTERISTIC N WITH CHARACTERISTIC N TOTAL % WITH CHARACTERISTIC
COMORBIDITIES
Pulmonary Hypertension* 73 222 32.8
ACS 354 475 74.5
CHF 28 470 6.0
AVN 150 461 32.5
Leg Ulcer 112 464 24.1
Stroke 73 465 15.7
Seizure 57 474 12.0
TIA 18 455 4.0
Retinopathy 103 443 23.3
Proteinuria 124 460 27.0
Gallstones 293 471 62.2
Chronic Transfusion 30 469 6.4
Priapism 80 215 37.2
SURGICAL HISTORY
Splenectomy 48 378 12.7
Cholecystectomy 257 383 67.1
MEDICATIONS
Iron Chelator 24 463 5.2
Hydroxyurea 184 441 41.7
Daily Long Acting Narcotics 120 374 32.1
Antihypertensives 73 447 16.3
Antidepressants 43 447 9.6
Bronchodilators 27 448 6.0
*
Defined as tricuspid regurgitant velocity ≥2.5 m/s by echocardiography
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TABLE III
Hazard ratios for characteristics measured as continuous variables including all genotypes.
TRAIT N HAZARD RATIO p-VALUE
Hemoglobin (off HU*) 362 1.21 0.0043
Hemoglobin (off HU) adjusted for GFR 319 0.93 0.3277
Hemoglobin (on HU) 168 1.36 0.0107
Hemoglobin (on HU) adjusted for GFR 157 0.83 0.1785
WBC (off HU) 351 1.06 0.0419
WBC (on HU)** 168 1.63 0.3181
Platelets (off HU) 350 1.00 0.9402
Platelets (on HU)** 167 0.65 0.3066
Fetal Hemoglobin (off HU)** 180 1.00 0.9954
Fetal Hemoglobin (on HU)** 124 0.79 0.3199
Ferritin** 153 1.27 0.0628
Mean Corpuscular Volume (off HU) 361 1.01 0.5220
Mean Corpuscular Volume (on HU) 168 1.02 0.2582
Lactate Dehydrogenase** 382 0.82 0.1621
Reticulocytes (off HU)** 313 1.01 0.9663
Hemolytic Index*** 313 1.10 0.3206
Total Bilirubin 410 1.01 0.8887
GFR 414 1.07 <0.0001
Body Mass Index 343 0.98 0.3138
Body Mass Index adjusted for HU 317 0.98 0.2711
NT-proBNP** 87 1.62 0.0004
sICAM-1 87 0.1376











denotes variables converted to logarithmic scale.
***
calculated in Hb SS and Hb Sβ0 subjects only
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